Jeil Pharma Holdings Inc (002620.KS)
KRW 7990.0
(-3.5%)
KRW 7990.0
(-3.5%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 173.03 Billion KRW | 26.7% |
| 2022 | 136.56 Billion KRW | 18.68% |
| 2021 | 115.07 Billion KRW | -23.18% |
| 2020 | 149.79 Billion KRW | 22.19% |
| 2019 | 122.59 Billion KRW | 6.53% |
| 2018 | 115.07 Billion KRW | 16858.64% |
| 2017 | 678.57 Million KRW | -98.81% |
| 2016 | 56.95 Billion KRW | 116.2% |
| 2015 | 26.34 Billion KRW | 68.59% |
| 2014 | 15.62 Billion KRW | 11.62% |
| 2013 | 14 Billion KRW | -42.57% |
| 2012 | 24.37 Billion KRW | 306.27% |
| 2011 | 6 Billion KRW | 0.0% |
| 2010 | 6 Billion KRW | 0.0% |
| 2009 | 6 Billion KRW | -45.45% |
| 2008 | 11 Billion KRW | 79.01% |
| 2007 | 6.14 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 151.11 Billion KRW | -11.12% |
| 2024 Q1 | 170.01 Billion KRW | -1.74% |
| 2023 Q2 | 161.54 Billion KRW | 10.16% |
| 2023 Q1 | 146.64 Billion KRW | 7.38% |
| 2023 FY | 173.03 Billion KRW | 26.7% |
| 2023 Q4 | 173.03 Billion KRW | 1.46% |
| 2023 Q3 | 170.54 Billion KRW | 5.57% |
| 2022 Q2 | 123.11 Billion KRW | 4.75% |
| 2022 Q1 | 117.53 Billion KRW | 2.14% |
| 2022 FY | 136.56 Billion KRW | 18.68% |
| 2022 Q4 | 136.56 Billion KRW | -1.37% |
| 2022 Q3 | 138.45 Billion KRW | 12.46% |
| 2021 Q3 | 125.26 Billion KRW | 7.73% |
| 2021 Q4 | 115.07 Billion KRW | -8.13% |
| 2021 FY | 115.07 Billion KRW | -23.18% |
| 2021 Q1 | 118.39 Billion KRW | -20.96% |
| 2021 Q2 | 116.27 Billion KRW | -1.79% |
| 2020 Q4 | 149.79 Billion KRW | 1.21% |
| 2020 Q2 | 136.44 Billion KRW | 16.09% |
| 2020 Q3 | 147.99 Billion KRW | 8.46% |
| 2020 FY | 149.79 Billion KRW | 22.19% |
| 2020 Q1 | 117.53 Billion KRW | -4.13% |
| 2019 Q2 | 85.53 Billion KRW | 1.38% |
| 2019 Q4 | 122.59 Billion KRW | 47.65% |
| 2019 Q1 | 84.36 Billion KRW | -26.69% |
| 2019 Q3 | 83.02 Billion KRW | -2.93% |
| 2019 FY | 122.59 Billion KRW | 6.53% |
| 2018 Q2 | 47 Billion KRW | 0.0% |
| 2018 Q3 | 47 Billion KRW | 0.0% |
| 2018 FY | 115.07 Billion KRW | 16858.64% |
| 2018 Q1 | - KRW | -100.0% |
| 2018 Q4 | 115.07 Billion KRW | 144.85% |
| 2017 Q1 | 43.57 Billion KRW | -23.5% |
| 2017 Q2 | 779.31 Million KRW | -98.21% |
| 2017 FY | 678.57 Million KRW | -98.81% |
| 2017 Q3 | 1.45 Billion KRW | 86.71% |
| 2017 Q4 | 678.57 Million KRW | -53.36% |
| 2016 FY | 56.95 Billion KRW | 116.2% |
| 2016 Q4 | 56.95 Billion KRW | 0.0% |
| 2015 Q2 | 14 Billion KRW | 0.0% |
| 2015 FY | 26.34 Billion KRW | 68.59% |
| 2015 Q3 | 25.26 Billion KRW | 80.5% |
| 2015 Q1 | 14 Billion KRW | -10.41% |
| 2014 Q1 | 17.89 Billion KRW | 27.79% |
| 2014 Q2 | 14 Billion KRW | -21.74% |
| 2014 Q3 | 14 Billion KRW | 0.0% |
| 2014 Q4 | 15.62 Billion KRW | 11.62% |
| 2014 FY | 15.62 Billion KRW | 11.62% |
| 2013 Q3 | 14 Billion KRW | -1.75% |
| 2013 Q4 | 14 Billion KRW | 0.0% |
| 2013 Q2 | 14.25 Billion KRW | 1.79% |
| 2013 Q1 | 14 Billion KRW | -42.57% |
| 2013 FY | 14 Billion KRW | -42.57% |
| 2012 Q3 | 19.3 Billion KRW | 8.65% |
| 2012 Q2 | 17.76 Billion KRW | 196.15% |
| 2012 Q1 | 6 Billion KRW | 0.0% |
| 2012 FY | 24.37 Billion KRW | 306.27% |
| 2012 Q4 | 24.37 Billion KRW | 26.26% |
| 2011 FY | 6 Billion KRW | 0.0% |
| 2011 Q4 | 6 Billion KRW | 0.0% |
| 2011 Q3 | 6 Billion KRW | 0.0% |
| 2011 Q2 | 6 Billion KRW | 0.0% |
| 2011 Q1 | 6 Billion KRW | 0.0% |
| 2010 Q1 | 6 Billion KRW | 0.0% |
| 2010 Q2 | 6 Billion KRW | 0.0% |
| 2010 FY | 6 Billion KRW | 0.0% |
| 2010 Q4 | 6 Billion KRW | 0.0% |
| 2010 Q3 | 6 Billion KRW | 0.0% |
| 2009 Q3 | 6 Billion KRW | -45.45% |
| 2009 Q2 | 11 Billion KRW | 0.0% |
| 2009 Q1 | 11 Billion KRW | 0.0% |
| 2009 FY | 6 Billion KRW | -45.45% |
| 2009 Q4 | 6 Billion KRW | 0.0% |
| 2008 Q1 | 6.34 Billion KRW | 3.26% |
| 2008 Q2 | 6.06 Billion KRW | -4.49% |
| 2008 Q4 | 11 Billion KRW | 74.23% |
| 2008 Q3 | 6.31 Billion KRW | 4.18% |
| 2008 FY | 11 Billion KRW | 79.01% |
| 2007 Q3 | 6.14 Billion KRW | -49.4% |
| 2007 FY | 6.14 Billion KRW | 0.0% |
| 2007 Q2 | 12.14 Billion KRW | 0.0% |
| 2007 Q4 | 6.14 Billion KRW | 0.0% |
| 2007 Q1 | 12.14 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -339.084% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 74.991% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 54.711% |
| HANDOK Inc. | 300.01 Billion KRW | 42.325% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -464.314% |
| Yuhan Corporation | 230.07 Billion KRW | 24.793% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 57.456% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -28957.043% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 69.796% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -13307.715% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -103.183% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -299.86% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | -91.232% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -552.132% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -339.084% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -72563.443% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 23.116% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 4.402% |
| JW Holdings Corporation | 554.58 Billion KRW | 68.8% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 20.57% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 21.265% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -1.615% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -274.919% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -341.349% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 1.62% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -103.648% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -339.084% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 26.57% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 63.16% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -1.615% |
| Yuhan Corporation | 230.07 Billion KRW | 24.793% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -158.71% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 63.016% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -1.615% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | -45.847% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -328.941% |
| CKD Bio Corp. | 146.92 Billion KRW | -17.767% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | -18.474% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -258.573% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -27277.146% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -274.919% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 63.03% |
| Boryung Corporation | 204.21 Billion KRW | 15.271% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -117.959% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -103.183% |
| JW Lifescience Corporation | 46.31 Billion KRW | -273.613% |